These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21151153)

  • 1. Cabazitaxel: a new drug for metastatic prostate cancer.
    Bilusic M; Dahut WL
    Asian J Androl; 2011 Mar; 13(2):185-6. PubMed ID: 21151153
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.
    Singer EA; Srinivasan R
    Urol Oncol; 2012; 30(4 Suppl):S15-9. PubMed ID: 22014836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
    Lovett R; Kelly V; Goodall M; Adler AI
    Lancet Oncol; 2016 Jul; 17(7):872-873. PubMed ID: 27234583
    [No Abstract]   [Full Text] [Related]  

  • 6. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
    Sartor O; Halstead M; Katz L
    Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
    Lheureux S; Joly F
    Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel for prostate cancer: patient preparation and ongoing care.
    Hardwick J
    Br J Nurs; 2012 May 10-23; 21(9):S13-7. PubMed ID: 22690408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubulin-targeted agents including docetaxel and cabazitaxel.
    Cheetham P; Petrylak DP
    Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
    Pal SK; Twardowski P; Sartor O
    Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
    Figg WD; Figg WD
    Cancer Biol Ther; 2010 Dec; 10(12):1233-4. PubMed ID: 21107022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
    Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC
    Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Demolis P; Moreau A; Hemmings RJ; O'Connor D; Brown D; Shepard T; Abadie E; Pignatti F
    Oncologist; 2012; 17(4):543-9. PubMed ID: 22477727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
    Pouessel D; Oudard S; Gravis G; Priou F; Shen L; Culine S
    Bull Cancer; 2012; 99(7-8):731-41. PubMed ID: 22743148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
    D'Amico AV
    J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.